Loader

Pathways

PathWhiz ID Pathway Meta Data

PW145934

Pw145934 View Pathway
drug action

Tedizolid phosphate Drug Metabolism Action Pathway

Homo sapiens

PW176143

Pw176143 View Pathway
metabolic

Tedizolid Predicted Metabolism Pathway new

Homo sapiens
Metabolites of Tedizolid are predicted with biotransformer.

PW146050

Pw146050 View Pathway
drug action

Tegafur Drug Metabolism Action Pathway

Homo sapiens

PW146093

Pw146093 View Pathway
drug action

Tegafur-uracil Drug Metabolism Action Pathway

Homo sapiens

PW145170

Pw145170 View Pathway
drug action

Tegaserod Drug Metabolism Action Pathway

Homo sapiens

PW127444

Pw127444 View Pathway
drug action

Teicoplanin Action Pathway

Staphylococcus aureus
Teicoplanin is a glycopeptide antibiotic with a similar mechanism of action and spectrum of activity to vancomycin used to treat various infections caused by gram-positive bacteria. It is used for the treatment of bacterial infections caused by susceptible microorganisms. It is a glycopeptide antiobiotic extracted from Actinoplanes teichomyceticus, with a similar spectrum of activity to vancomycin. Its mechanism of action is to inhibit bacterial cell wall synthesis. Teicoplanin inhibits peptidoglycan polymerization, resulting in inhibition of bacterial cell wall synthesis and cell death. Oral teicoplanin has been demonstrated to be effective in the treatment of pseudomembranous colitis and Clostridium difficile-associated diarrhoea, with comparable efficacy to vancomycin. Teicoplanin is poorly absorbed after oral administration but is 90% bioavailable when administered intramuscularly.

PW145661

Pw145661 View Pathway
drug action

Teicoplanin Drug Metabolism Action Pathway

Homo sapiens

PW127527

Pw127527 View Pathway
drug action

Telaprevir Action Pathway

Homo sapiens
Telaprevir is an NS3/4A viral protease inhibitor used in combination with other antivirals for the curative treatment of chronic Hepatitis C Virus infections. Hepatitis C virus lipoviroparticles enter target hepatocytes via receptor-mediated endocytosis. The lipoviroparticles attach to LDL-R and SR-B1, and then the virus binds to CD81 and subsequently claudin-1 and occludin, which mediate the late steps of viral entry. The virus is internalized by clathrin-dependent endocytosis. RNA is released from the mature Hepatitis C virion and translated at the rough endoplasmic reticulum into a single Genome polyprotein. Paritaprevir accumulates in the liver after uptake into hepatocytes via solute carrier organic anion transporter family member 1B1. Paritaprevir inhibits NS3/4A protease, which is an enzyme that cleaves the heptatitis C virus polyprotein downstream of the NS3 proteolytic site, which generates nonstructural proteins NS3, NS4A, NS4B, NS5A, and NS5B. These proteins are required in viral RNA replication, therefore because of the inhibition of their formation, RNA replication cannot occur. Because RNA replication does not occur, the mature virion is unable to form. At higher concentration above their antiviral half-maximal effective concentration (EC50), Paritaprevir and other NS3/4A inhibitors also restore interferon (IFN)-signaling pathways that are thought to be disrupted by NS3/4A protease and recover innate immune processes. NS3/4A protease cleaves two essential adaptor proteins that initiate signaling leading to activation of IFN regulatory factor 3 and IFN-α/β synthesis, which are mitochondrial antiviral-signaling proteins.

PW145645

Pw145645 View Pathway
drug action

Telaprevir Drug Metabolism Action Pathway

Homo sapiens

PW176144

Pw176144 View Pathway
metabolic

Telaprevir Predicted Metabolism Pathway new

Homo sapiens
Metabolites of Telaprevir are predicted with biotransformer.